Bergenstal, Richard M. http://orcid.org/0000-0002-9050-5584
Bode, Bruce W.
Bhargava, Anuj
Wang, Qianqian
Knights, Alastair W.
Chang, Annette M.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 17 July 2023
Accepted: 7 September 2023
First Online: 23 September 2023
Declarations
:
: Richard M. Bergenstal has received research support, consulted, or has been on a scientific advisory board for Abbott Diabetes Care, Ascensia, CeQur, Dexcom, Eli Lilly and Company, Glooko, Hygieia, Johnson & Johnson, Medtronic, Merck, Novo Nordisk, Onduo, Roche, Sanofi, United Healthcare and Zealand. Richard M. Bergenstal’s employer, nonprofit HealthPartners Institute, contracts for his services, and no personal income goes to Richard M. Bergenstal. Bruce W. Bode is a shareholder of Aseko, Inc. and has received consultant fees from Eli Lilly and Company, Lexicon, Medtronic, Novo Nordisk, and Pfizer; and speaker honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Mannkind, Medtronic, Novo Nordisk, Sanofi, Senseonics, and Xeris. Bruce W. Bode is an employee of Atlanta Diabetes Associates. Atlanta Diabetes Associates has received research grants and support from Boehringer Ingelheim, Dexcom, Diasome, Eli Lilly and Company, Insulet, Janssen, Lexicon, Mannkind, Medtronic, National Institutes of Health (NIH), Nova Biomedical, Novo Nordisk, Provention Bio, Sanofi, Senseonics, REMD Biotherapeutics, VtV Therapeutics LLC, and Xeris. Anuj Bhargava has received research grants from Abbott Diabetes Care, AbbVie, Boehringer Ingelheim, Boston Therapeutics, Covance, Dexcom, Eli Lilly and Company, Gan & Lee Pharmaceuticals, Insulet Corporation, Kowa Pharmaceuticals America, Lexicom, Madrigal Pharmaceuticals, Medtronic, Novo Nordisk, Poxel, Quintiles, Sanofi, Senseonics, Tolerion, Viking Therapeutics, and VtV Therapeutics. Qianqian Wang, Alastair W. Knights, and Annette M. Chang are employees and shareholders of Eli Lilly and Company.
: The study was conducted at three centers in the United States in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, and applicable local laws and regulations. The study protocol and all procedures were reviewed and approved by an ethics review board for each study center (Healthpartners Institute Dba International Diabetes Center, Bloomington, MN; or Western Institutional Review Board – Connexus, Puyallup, WA). All participants provided written informed consent before participating in the study. All authors gave approval for the final version of the manuscript to be published.